Changing Priorities in Vaccinology Pushes Veterinary Vaccines Forward as the Most Powerful Tool in the Battle Against Antibiotic Resistance

Growing concerns over antibiotic resistance especially in farm animals and the resulting rise in the value of vaccines in preventing and combating antimicrobial resistance; rise in responsible pet ownership; spread of zoonotic diseases; increasing government spending on research and development of innovative, newer and better second-generation veterinary vaccines are poised to drive the global market for Veterinary Vaccines to reach US$10.5 billion by 2024.

Worldwide, growing demand for meat and other animal products such as eggs and dairy products alongside growing pet ownership are the major factors driving demand for animal vaccines. Increasing prevalence of animal diseases driven in part by rising production densities, growing incidences of zoonotic diseases, increasing investments in vaccine research and product development, rising pressure to eliminate or reduce use of antibiotics, growing awareness related to animal health issues and available treatment options, increasing government spending on research and efforts to manage disease outbreaks, continuing product innovations and emergence of new and effective products are the major factors driving growth in the global veterinary vaccines market.

Earlier vaccine programs in animals have successfully eradicated several diseases and encouraged yield of various farm animals. However, reemergence of certain diseases, emergence of exotic diseases such as avian influenza and rise of new diseases are pushing the need for new and technologically advanced vaccines. Over the years, the veterinary vaccines market witnessed considerable developments at the product front. Technological innovations are also contributing to growth in the veterinary vaccines market, which include adoption of diverse approaches to vaccine development, including whole-pathogen preparations, genetically engineered organisms, naked DNA injections, vectored antigen formulations and subunit vaccines defined molecularly. These efforts led to successful development of vaccines against a range of multicellular and protozoal, bacterial and viral pathogens. Ongoing research in this space is expected to further result development of more effective products for presently targeted and new diseases. However, factors such as high cost of vaccines, higher maintenance costs of vaccines such as in their storage and increasing preference for vegetarian food in some markets are hindering marketing growth.

Within the veterinary vaccines market, livestock vaccines take up a larger market share than companion animal vaccines, on account of higher production demands in the Western markets and the dependence on livestock for sustenance in the developing countries. Companion animals have increasingly become pets and expenditure on them to ensure their well-being has been on the rise. Awareness programs conducted by animal welfare groups have played a key role in increasing awareness regarding animal diseases among livestock and pet owners.  Owing to these factors, veterinary vaccines have surged in demand.

As stated by the new market research report on Veterinary Vaccines, the United States represents the largest market worldwide, driven by well-developed veterinary infrastructure supporting the livestock and companion animal industries. The emerging economies of Asia, particularly China, on the other hand, are expected to see increased growth rates through the review period due to higher investment opportunities for major companies.

Major players in the market include Bayer de México SA de CV, Biogénesis Bagó SA, Boehringer Ingelheim International GmbH, Ceva Santé Animale, Elanco Animal Health, Heska Corporation, Indian Immunologicals Ltd., Merck Animal Health, Virbac SA, and Zoetis Inc.

The research report titled “Veterinary Vaccines - Market Analysis, Trends, and Forecasts” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections for all major geographic markets, such as the US, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific (China and Rest of Asia-Pacific), and Rest of World. Product segments analyzed in the report include Companion Animal Vaccines (Canine Vaccines and Feline Vaccines) and Livestock Vaccines (Porcine Vaccines, Bovine Vaccines, Poultry Vaccines, Ovine Vaccines, Equine Vaccines, and Other Livestock Vaccines). 

For enquiries e-mail us at rsd@strategyr.com or info411@strategyr.com.

For cutting edge analyst reviews on top industries

Follow us on Twitter; Connect with us on LinkedIn; Follow us on Medium